Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

OBJECTIVE: To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies. METHODS: A partitioned survival model that in...

Descripción completa

Detalles Bibliográficos
Autores principales: Campioni, M., Agirrezabal, I., Hajek, R., Minarik, J., Pour, L., Spicka, I., Gonzalez-McQuire, S., Jandova, P., Maisnar, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072050/
https://www.ncbi.nlm.nih.gov/pubmed/31673898
http://dx.doi.org/10.1007/s10198-019-01122-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072050/
https://www.ncbi.nlm.nih.gov/pubmed/31673898
http://dx.doi.org/10.1007/s10198-019-01122-6

Ejemplares similares